The Pill and Your Libido: What the Research Actually Says

A Pharmacologic Effect That Gets Discussed, But Not Always Clearly

Combined hormonal contraception — most commonly the combined oral contraceptive pill (COC), but also the vaginal ring, transdermal patch, and combined injectable — has a real, well-documented effect on your body's testosterone system. The effect is not controversial in the endocrinology literature: combined estrogen-containing contraceptives raise liver-derived sex hormone binding globulin (SHBG), which in turn reduces circulating free testosterone.

What is more nuanced, and what this article is about, is what that effect means for individual clinical experience, what the published literature says about recovery after discontinuation, and how the major guideline bodies frame the issue.

This is a research review. It does not recommend that any individual reader continue or discontinue hormonal contraception. That is a clinical decision made with a prescribing physician, involving considerations (pregnancy prevention, menstrual regulation, acne, PCOS management, endometriosis, and many others) that fall well outside the scope of any single-axis discussion. What this article can do is summarize what the published research actually shows on this specific pharmacologic effect, which is frequently misrepresented in both directions.

How Combined Hormonal Contraception Affects SHBG

SHBG is produced in the liver. Oral ethinyl estradiol — the estrogen component in nearly all combined oral contraceptives — has particularly potent effects on hepatic protein synthesis because of first-pass liver exposure. The liver sees a concentration of synthetic estrogen that is different in kind from what the liver sees from the estrogen your own body makes at normal levels.

The published pharmacokinetic and clinical data show:

SHBG rises substantially on combined oral contraception. Multiple studies have documented SHBG increases of 2- to 4-fold with combined oral contraceptive use, depending on the specific formulation, progestin component, and baseline SHBG.^[1] The magnitude varies — some women experience modest elevation, others substantial elevation — but the direction of effect is consistent across the literature.

Free testosterone falls as a consequence. Because SHBG binds circulating testosterone, an increase in SHBG reduces the free fraction. Free testosterone measurements are reliably lower when women are on the pill than before they started, even if total testosterone barely moves. This is basic binding chemistry — not a controversial finding.

Non-oral combined contraception has smaller effects. The vaginal ring and transdermal patch contain ethinyl estradiol but produce smaller SHBG elevations than oral forms because the liver first-pass effect is partially bypassed. Progestin-only methods (progestin-only pill, hormonal IUD, implant, injectable) have minimal SHBG effects in most studies.

Different progestins have different androgenic profiles. Older-generation progestins (norethindrone, levonorgestrel) have intrinsic androgenic activity. Newer progestins (drospirenone, norgestimate, desogestrel, dienogest) have lower androgenic activity or anti-androgenic activity. These differences modestly modulate the net androgen impact of a given pill.

The pharmacology is well-characterized. What has been more contested is the clinical significance of the free testosterone reduction and what happens after discontinuation.

The Panzer 2006 Study and Subsequent Research

One of the most frequently cited studies in this literature is Panzer et al., published in the Journal of Sexual Medicine in 2006.^[1] The study was a retrospective analysis of 124 women presenting to a sexual dysfunction clinic. It reported that SHBG levels were significantly elevated in current oral contraceptive users compared to never-users and that elevated SHBG persisted in past users who had discontinued up to one year prior.

The paper has been influential and widely cited, including in the ISSWSH guideline on women's sexual health. It has also been the subject of subsequent research reassessment. Important context:

Sample population. The Panzer study population was women presenting to a sexual dysfunction clinic, not a general-population sample. Generalization to asymptomatic women is uncertain.

Retrospective design. The study was retrospective and didn't have a pre-pill SHBG measurement to compare against. Women who were past users had their baseline SHBG measured only after discontinuation.

Subsequent literature is mixed on reversibility. A 2013 systematic review by Burrows and colleagues concluded that most studies show SHBG returns toward baseline within 6-12 months of discontinuation, though individual variation is substantial.^[2] A subset of studies have documented persistent elevation in some individuals beyond that timeline; the factors that predict persistence are not well-characterized.

The honest summary of this body of research is that SHBG elevation on combined oral contraception is a robust and reproducible finding, and that SHBG generally recovers toward baseline after discontinuation over a period of months, though individual variation exists. Claims of permanent and irreversible SHBG elevation from past contraceptive use are not well-supported by the aggregate published literature. Claims that contraception has no meaningful impact on the androgen axis are also not well-supported.

Readers interested in the broader context of SHBG as a variable in female hormone interpretation may find the overview in understanding the hormonal landscape of midlife in women useful.

What the Clinical Effects Look Like in the Literature

The pharmacologic effect (higher SHBG, lower free testosterone) is well-documented. The clinical question — whether individual women experience symptomatic consequences — is more heterogeneous in the literature.

Sexual function and desire. A subset of the sexual medicine literature has examined sexual function in combined oral contraceptive users compared to non-users. Findings are mixed. Some studies report reduced sexual desire in combined oral contraceptive users; others report no difference or mixed effects. Meta-analyses have not produced a consistent signal across all outcomes. The ISSWSH consensus and sexual medicine guidelines generally acknowledge that some women may experience sexual desire changes on combined oral contraception and that switching formulations or methods is one clinical option when this occurs.

Mood. A large Danish cohort study by Skovlund et al., published in JAMA Psychiatry in 2016, reported that hormonal contraceptive use was associated with modestly elevated rates of first antidepressant prescription, particularly in adolescents.^[1] Subsequent research has nuanced these findings — critics pointed out the limits of this kind of study — it tracks associations, not cause and effect, and replication across different populations has produced mixed results. The honest summary is that hormonal contraception's relationship to mood is real but small on average and highly variable across individuals.

Other androgen-mediated effects. Acne improvement is a well-documented favorable effect of combined oral contraception, driven primarily by the SHBG-mediated reduction in free testosterone. Androgenic alopecia improvement is similarly documented. These are the intended effects used clinically to treat hyperandrogenic conditions.

The same pharmacologic mechanism that produces desired effects in some clinical contexts produces effects that some women experience as undesirable in others. This is a feature of how the medication works, not a flaw in any particular patient's experience.

What the Guidelines Actually Say

The major gynecology and sexual medicine bodies have addressed this question in published guidance. Summary of the positions:

American College of Obstetricians and Gynecologists (ACOG). ACOG's position, as expressed in committee opinions and practice bulletins, is that combined hormonal contraception is broadly safe and effective for pregnancy prevention and many non-contraceptive indications. Sexual side effects are acknowledged as possible in a minority of users, and clinicians are advised to consider alternative methods if significant side effects occur.

ISSWSH. The ISSWSH literature and guidelines acknowledge that combined hormonal contraception can reduce free testosterone and may contribute to sexual dysfunction in some women. Clinical management options discussed in the literature include switching to a lower-dose or different-progestin oral contraceptive, switching to a non-oral combined method, switching to a progestin-only method, or discontinuing hormonal contraception and using non-hormonal methods.

The Menopause Society (NAMS). Most NAMS guidance is focused on postmenopausal populations and addresses hormonal contraception primarily in the perimenopause-to-postmenopause transition context.

Endocrine Society. The Endocrine Society's Clinical Practice Guideline on androgen therapy in women mentions combined oral contraception as a factor that lowers free testosterone through SHBG elevation, relevant when evaluating a woman's androgen status.

What all guideline bodies emphasize, in their own language, is that decisions about contraception are individualized and involve weighing many considerations beyond the androgen axis. No guideline body tells women to stop contraception because of the SHBG issue. They just say it's one thing your doctor should factor in.

Why This Shows Up in Women's Hormone Optimization Discussions

This topic surfaces in women's hormone optimization and sexual medicine discussions for a specific reason: a meaningful minority of women who present with low libido, low energy, or suboptimal sexual function turn out to have high SHBG driven by combined oral contraceptive use. Once that pattern is identified on bloodwork, the clinical question becomes how to interpret and manage it.

The available clinical approaches, documented in sexual medicine and women's hormone optimization literature, include:

Method change within the contraceptive space. Switching from a higher-androgenic-impact formulation to a lower-impact one, or from a combined method to a progestin-only or non-hormonal method, if pregnancy prevention remains the priority and other clinical factors permit.

Watchful waiting after discontinuation. If a woman and her physician decide to discontinue combined hormonal contraception, monitoring SHBG and free testosterone recovery over a period of months.

Adjunctive testosterone therapy. In selected clinical contexts, particularly in postmenopausal women with HSDD, testosterone therapy can be layered in. The ISSWSH guideline supports this for postmenopausal HSDD; the evidence base in premenopausal women is weaker. See the US prescribing landscape for female testosterone for more on that category.

None of these approaches is universally recommended. They are options that a prescribing physician may consider in the context of an individual patient's presentation, contraceptive needs, and preferences. The important framing, and one this article cannot overemphasize: contraception decisions happen in a doctor's office, not in a blog post.

How to Engage With This Literature

Readers who want to understand this area beyond a summary article have several productive entry points:

Primary research. Panzer et al. 2006 is the most-cited starting point. Burrows et al. 2013 systematic review provides the reversibility data. Skovlund et al. 2016 (JAMA Psychiatry) is the large cohort study on mood. The ISSWSH guideline and Endocrine Society guideline cite the full primary literature and are accessible.

Physician voices that cover this carefully. A number of contemporary clinicians have written publicly about contraception and the androgen axis with appropriate nuance. See the reading list of voices shaping women's biohacking in 2026 for specific names.

Your own prescribing physician. This is a topic where the published literature is useful context but the clinical application requires individualized evaluation. A physician with specific expertise in women's sexual medicine or hormone optimization is the appropriate person to help interpret any particular woman's labs, history, and preferences.

The core empirical points are well-established. The clinical application is individualized. Both can be true.

Footnotes

^[1]: Panzer C, Wise S, Fantini G, et al. "Impact of oral contraceptives on sex hormone-binding globulin and androgen levels: a retrospective study in women with sexual dysfunction." Journal of Sexual Medicine, 2006; 3(1): 104-113. ^[2]: Burrows LJ, Basha M, Goldstein AT. "The effects of hormonal contraceptives on female sexuality: a review." Journal of Sexual Medicine, 2012; 9(9): 2213-2223. See also systematic reviews in the following years updating the evidence base on recovery. ^[3]: Skovlund CW, Morch LS, Kessing LV, Lidegaard O. "Association of hormonal contraception with depression." JAMA Psychiatry, 2016; 73(11): 1154-1162.